{"id":"NCT00810693","sponsor":"Bayer","briefTitle":"A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)","officialTitle":"Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-17","primaryCompletion":"2012-05-14","completion":"2012-05-14","firstPosted":"2008-12-18","resultsPosted":"2014-02-26","lastUpdate":"2023-11-22"},"enrollment":445,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"Riociguat (Adempas, BAY63-2521)","otherNames":[]},{"type":"DRUG","name":"Riociguat (Adempas, BAY63-2521)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT","type":"EXPERIMENTAL"},{"label":"Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).","primaryOutcome":{"measure":"6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12","timeFrame":"Baseline and week 12","effectByArm":[{"arm":"Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT","deltaMin":29.6,"sd":65.8},{"arm":"Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT","deltaMin":31.1,"sd":79.3},{"arm":"Placebo","deltaMin":-5.6,"sd":85.5}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":122,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Japan","Mexico","New Zealand","Poland","Portugal","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["23883383","23883378","26135803","27326239","27263466","34848133","35256218","34353714","27457511","27162632"],"seeAlso":["https://clinicaltrials.bayer.com/study/12934"]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":254},"commonTop":["Headache","Oedema peripheral","Dizziness","Dyspepsia","Nausea"]}}